Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer

被引：16
|
作者：
Tomasini, Pascale [1 ,2 ]
Greillier, Laurent [1 ,2 ]
Boyer, Arnaud [1 ,2 ]
Jeanson, Arnaud [1 ,2 ]
Barlesi, Fabrice [1 ,2 ]
机构：
[1] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, AP HM, Marseille, France
[2] Aix Marseille Univ UM105, Inserm UMR1068, CNRS UMR7258, Predict Oncol Lab,Ctr Rech Cancerol Marseille, Marseille, France
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
TREMELIMUMAB COMBINATION THERAPY; PLATINUM-BASED CHEMOTHERAPY; 1ST-LINE TREATMENT; PLUS TREMELIMUMAB; PATIENTS PTS; MEDI4736; PHASE-3; NSCLC; RADIOTHERAPY; MULTICENTER;
D O I：
10.21037/jtd.2018.04.61
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1032 / S1036
页数：5
相关论文
共 50 条
  • [41] Chemoradiotherapy for poor-risk stage III non-small cell lung cancer
    Lau, DHM
    Ryu, JK
    Gandara, DR
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 110 - 112
  • [42] Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer
    Naito, Yoichi
    Kubota, Kaoru
    Nihei, Keiji
    Fujii, Tomonori
    Yoh, Kiyotaka
    Niho, Seiji
    Goto, Koichi
    Ohmatsu, Hironobu
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : 617 - 622
  • [43] Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
    Raben, D.
    Rimner, A.
    Senan, S.
    Broadhurst, H.
    Pellas, T.
    Dennis, P. A.
    Faivre-Finn, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 683 - 683
  • [44] Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
    De Ruysscher, Dirk
    Remon, Jordi
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 149 - 151
  • [45] Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
    Yuto Terashima
    Taiki Hakozaki
    Yuji Uehara
    Akihiko Miyanaga
    Kazuo Kasahara
    Masahiro Seike
    Yukio Hosomi
    International Journal of Clinical Oncology, 2024, 29 : 115 - 123
  • [46] Real world assessment of clinical benefit with consolidation durvalumab following chemoradiotherapy in stage III unresectable non-small cell lung cancer
    Marur, Shanthi
    Mangurian, Mark
    Wise, Corey
    Pozotrigo, Melissa
    Marur, Shika
    Norden, Andrew D.
    Toler, Andrew
    Bobolts, Laura Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
    Terashima, Yuto
    Hakozaki, Taiki
    Uehara, Yuji
    Miyanaga, Akihiko
    Kasahara, Kazuo
    Seike, Masahiro
    Hosomi, Yukio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 115 - 123
  • [48] Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab
    Tuller, M.
    Buela, G.
    Ferreira, Y.
    Antivero, A.
    Lupinacci, L.
    Basbus, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S607 - S608
  • [49] Who Benefits Most from Adjuvant Durvalumab after Chemoradiotherapy for Non-Small Cell Lung Cancer?
    Ohri, N.
    Halmos, B.
    Bodner, W. R., III
    Cheng, H.
    Garg, M. K.
    Gucalp, R.
    Guha, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E85 - E86
  • [50] Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
    Pennock, Michael
    Halmos, Balazs
    Bodner, William
    Cheng, Haiying
    Gucalp, Rasim
    Ohri, Nitin
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 41
12345